The burgeoning field of real-world evidence (RWE) is transforming how medical professionals and regulators understand the long-term effects of therapeutics,…
Read More
AI Can Accelerate Study-Build Foundations, But Only When Teams Combine Targeted Automation with Standards, Traceability and Control.
Artificial intelligence (AI) is rapidly transforming various sectors, and clinical data management is no exception. While the potential applications of…
Read More
BMS claims pharma’s most powerful AI supercomputer. How it stacks up to Lilly’s and Roche’s.
Bristol Myers Squibb (BMS) announced Monday its plans to deploy an NVIDIA DGX SuperPOD, a cutting-edge, prepackaged supercomputing platform designed…
Read More
Navigating the New Frontier: American Biotech’s Strategic Imperatives Amidst Global Competition and Shifting Investment Tides
For several years, the landscape for American biotechnology firms has grown increasingly challenging, with success becoming a more elusive commodity.…
Read More
Arrowfly Emerges as the New Corporate Identity for WTWH Media, Signaling Strategic Expansion and Market Consolidation
Cleveland, Ohio – In a significant corporate development signaling a strategic evolution and a unified market approach, WTWH Media, the…
Read More
Boehringer Ingelheim Eyes MASH as the Next Front for Survodutide, a GLP-1/Glucagon Receptor Dual Agonist
For decades, fatty liver disease, specifically metabolic dysfunction-associated steatotic liver disease (MASLD), and its more severe inflammatory form, metabolic dysfunction-associated…
Read More
ADA Conference Marked by Landmark GLP-1 Trial Results Amidst Unprecedented Scientific Dissent and Police Intervention
The annual national conference of the American Diabetes Association (ADA) this week served as a dual stage: a vibrant forum…
Read More
How CTF is trying to rescue pharma’s shelved rare disease drugs
More than 5,000 potential treatments for rare diseases are currently languishing on pharmaceutical company shelves, representing a vast, untapped reservoir…
Read More
Johnson & Johnson’s Spravato Remission Data Takes Center Stage in Push for Treatment-Resistant Depression Growth
A recent poster presentation at Psych Congress Elevate by Johnson & Johnson has placed esketamine nasal spray, marketed as Spravato,…
Read More
CNPV: A gamechanger for the pharma industry or simply more chaos?
The pharmaceutical industry finds itself at a pivotal juncture with the advent of the U.S. Food and Drug Administration’s (FDA)…
Read MoreYOU MAY HAVE MISSED
